Abstract
Temozolomide is an effective alkylating agent that is increasingly used for the treatment of pediatric brain tumors. Secondary, or treatment-related, myelodysplasia is a life-threatening complication of alkylating chemotherapy and has been reported in children with brain tumors after treatments other than temozolomide. We describe for the first time a case of temozolomide-related myelodysplasia in a child.
MeSH terms
-
Antineoplastic Agents, Alkylating / adverse effects*
-
Brain Neoplasms / complications*
-
Brain Neoplasms / drug therapy
-
Brain Neoplasms / radiotherapy
-
Child
-
Combined Modality Therapy
-
Cranial Irradiation
-
Dacarbazine / adverse effects
-
Dacarbazine / analogs & derivatives*
-
Fatal Outcome
-
Humans
-
Male
-
Myelodysplastic Syndromes / chemically induced*
-
Myelodysplastic Syndromes / genetics
-
Myelodysplastic Syndromes / pathology
-
Temozolomide
Substances
-
Antineoplastic Agents, Alkylating
-
Dacarbazine
-
Temozolomide